Oregon Health & Science University (OHSU)
Oregon Health & Science University (OHSU)
Portland, Oregon, United States25 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Recruiting | Phase 1 | 2026-10-06 | NCT07226843 | |
| Platform of Randomized Adaptive Clinical Trials in Critical Illness | Respiration Disorders, respiratory failure, respiratory system disorder | Recruiting | Not applicable | 2026-10-06 | NCT05440851 | |
| A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy | Symptomatic Genetic Dilated Cardiomyopathy | Recruiting | Phase 2 / Phase 3 | 2026-10-05 | NCT07210723 | |
| A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy | Symptomatic Genetic Dilated Cardiomyopathy (DCM) | Recruiting | Phase 3 | 2026-10-02 | NCT07771465 | |
| A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Phase 2 | 2026-10-02 | NCT06680830 | |
| The PIONEER Comparative Effectiveness Study - Project 2 | Brain Concussion, Brain Injuries, Traumatic, Craniocerebral Trauma, Disease Attributes, Emergencies, Head Injuries, Closed, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Wounds, Nonpenetrating, brain disorder, brain injury, central nervous system disorder, injury, nervous system disorder, nervous system injury | Not yet recruiting | Not applicable | 2026-09-22 | NCT07829107 | |
| A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Nutritional and Metabolic Diseases, familial hypercholesterolemia, hereditary disease, homozygous familial hypercholesterolemia, hyperlipidemia, hyperlipoproteinemia, hyperlipoproteinemia type V, hypertriglyceridemia, inborn errors of metabolism, metabolic disease | Recruiting | Phase 1 | 2026-09-18 | NCT07491172 | |
| ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™ | aortic valve disorder, aortic valve insufficiency, cardiovascular disorder, heart disorder, heart valve disorder | Recruiting | Not applicable | 2026-09-17 | NCT06608823 | |
| A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam) | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 2 | 2026-09-17 | NCT06223360 | |
| A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome | Epilepsies, Myoclonic, Epilepsy, Generalized, Epileptic Syndromes, brain disorder, central nervous system disorder, epilepsy, nervous system disorder | Recruiting | Phase 3 | 2026-08-24 | NCT06872125 | |
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, in situ carcinoma, neoplasm, superficial urinary bladder carcinoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 1 / Phase 2 | 2026-08-07 | NCT04752722 | |
| A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM) | aortic valve disorder, aortic valve stenosis, cardiomyopathy, cardiovascular disorder, heart disorder, heart valve disorder, hypertrophic cardiomyopathy, subvalvular aortic stenosis | Active, not recruiting | Phase 2 | 2026-07-31 | NCT06347159 | |
| Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 3 | 2026-07-02 | NCT06578247 | |
| (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, gastrointestinal stromal tumor, metastatic malignant neoplasm, neoplasm | Recruiting | Phase 3 | 2026-06-16 | NCT05208047 | |
| A Prospective Cohort Post Market Registry Evaluating Outcomes of Bridge-Enhanced ACL Restoration (BEAR®) | Anterior Cruciate Ligament Injuries, Knee Injuries, Leg Injuries, injury | Active, not recruiting | Not stated | 2026-06-09 | NCT05398341 | |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, sarcoma, skin disorder, skin neoplasm, squamous cell carcinoma | Active, not recruiting | Early phase 1 | 2026-05-22 | NCT04541108 | |
| ADAPT - A Patient Registry of the Real-world Use of Orenitram® | lung disorder, pulmonary arterial hypertension, pulmonary hypertension, respiratory system disorder | Active, not recruiting | Not stated | 2026-04-02 | NCT03045029 | |
| A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases | Muscle Weakness, Neoplasms by Site, Neurologic Manifestations, Neuromuscular Manifestations, Paraneoplastic Syndromes, Nervous System, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, muscle tissue disorder, musculoskeletal system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 1 | 2026-02-25 | NCT06626919 | |
| Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2026-02-11 | NCT05396885 | |
| FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors | Solid Tumor | Recruiting | Phase 1 | 2026-01-30 | NCT06809114 | |
| AMEND TS Early Feasibility Study | cardiovascular disorder, heart disorder, heart valve disorder, mitral valve insufficiency | Recruiting | Not applicable | 2026-01-07 | NCT06951672 | |
| A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, autosomal dominant Parkinson disease 4, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, type 1 diabetes mellitus 12 | Active, not recruiting | Phase 2 | 2025-09-04 | NCT05608044 | |
| A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02) | Hypovolemia, Infections, Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Shock, Systemic Inflammatory Response Syndrome, toxic shock syndrome | Recruiting | Phase 3 | 2025-04-04 | NCT06072430 | |
| Optimizing Stroke Prophylaxis of Acute Atrial Fibrillation With an Electronic Clinical Decision Support Tool | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorder | Enrolling by invitation | Not applicable | 2025-03-20 | NCT05341986 | |
| Pilot Study of Open Label Homocysteine Management Therapy in Levodopa-treated Parkinson's Disease | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Not applicable | 2025-01-13 | NCT06772220 |